Pharmacological Control of the Mevalonate Pathway: Effect on Arterial Smooth Muscle Cell Proliferation
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The mevalonate (MVA) pathway is involved in cell proliferation. We investigated drugs acting at different enzymatic steps on rat aorta smooth muscle cell (SMC) proliferation. Competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (0.1-10 microM) dose-dependently decreased (up to 90%) SMC proliferation. This effect was prevented by 100 microM MVA, 10 microM all-trans farnesol (F-OH) and 5 microM all-trans geranylgeraniol (GG-OH), precursors of protein prenyl groups, but not by 2-cis GG-OH, precursor of dolichols, squalene and ubiquinone. The same inhibitory effect was obtained with 6-fluoromevalonate (1-50 microM), an inhibitor of MVA-pyrophosphate decarboxylase. Partial recovery of cell proliferation was possible by all-trans F-OH and all-trans GG-OH, but not MVA. Squalestatin 1 (1-25 microM), a potent squalene synthase inhibitor, blocked cholesterol synthesis and slightly inhibited (21% decrease) SMC proliferation only at the highest tested concentration. NB-598 (1-10 microM), a potent squalene epoxidase inhibitor, blocked cholesterol synthesis without affecting SMC proliferation. Finally, the benzodiazepine peptidomimetic BZA-5B (10-100 microM), a specific inhibitor of protein farnesyltransferase, time- and dose-dependently decreased SMC proliferation (up to 62%) after 9 days. This effect of BZA-5B was prevented by MVA and all-trans GG-OH, but not by all-trans F-OH. SMC proliferation was not affected by the closely related compound BZA-7B, which does not inhibit protein farnesyltransferase. Altogether, these findings focus the role of the MVA pathway in cell proliferation and call attention to the involvement of specific isoprenoid metabolites, probably through farnesylated and geranylgeranylated proteins, in the control of this cellular event.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of the mevalonate pathway
Goldstein, J. L., & Brown, M. S. (1990) · Nature · doi:10.1038/343425a0 · Cited by 5,394
Cited by
New insights into the pharmacodynamic and pharmacokinetic properties of statins
Corsini, A., Bellosta, S., Baetta, R., Fumagalli, R., Paoletti, R., & Bernini, F. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00045-5 · Cited by 796
Self-citationStatin effects beyond lipid lowering—are they clinically relevant?
Bonetti, P. (2003) · European Heart Journal · doi:10.1016/s0195-668x(02)00419-0 · Cited by 527
Non-lipid-related effects of statins
Bellosta, S., Fed, N., Bernini, F., Paoletti, R., & Corsini, A. (2000) · Annals of Medicine · doi:10.3109/07853890008998823 · Cited by 333
Self-citationCholesterol starvation decreases P34 cdc2 kinase activity and arrests the cell cycle at G2
Martínez‐Botas, J., Suárez, Y., Ferruelo, A. J., Gómez‐Coronado, D., & Lasunció, M. A. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.11.1359 · Cited by 72
Lupo, M. G., Marchianò, S., Adorni, M. P., Zimetti, F., Ruscica, M., Greco, M. F., Corsini, A., & Ferri, N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084114 · Cited by 15
Self-citation
Metadata
- Authors
- Raiteri, M., Arnaboldi, L., Mcgeady, P., Gelb, M. H., Verri, D., Tagliabue, C., Quarato, P., Ferraboschi, P., Santaniello, E., Paoletti, R., Fumagalli, R., & Corsini, A.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 1997-06
- Volume
- 281
- Issue
- 3
- Pages
- 1144-1153
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2286757458
- Cited by
- 101
- References
- 1
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacological Control of the Mevalonate Pathway: Effect on Arterial Smooth Muscle Cell Proliferation. https://app.cochat.ai/papers/10.1016/s0022-3565(24)36722-9
- The paper
- Raiteri, M., Arnaboldi, L., Mcgeady, P., Gelb, M. H., Verri, D., Tagliabue, C., Quarato, P., Ferraboschi, P., Santaniello, E., Paoletti, R., Fumagalli, R., & Corsini, A. (1997). Pharmacological Control of the Mevalonate Pathway: Effect on Arterial Smooth Muscle Cell Proliferation. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1016/s0022-3565(24)36722-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.